Activation And Control Mechanisms Of The Plasma Kinin-Forming System And Its Relationship To Coagulation And Fibrinolysis  by Kaplan, Allen P
THE JOURNAL or INVESTIG ATIVE D ERMATOLOGY. 67:635-637. 1976 
Copyright © 1976 by The Williams & Wilk ins Co. 
Vol. 67. !\o. 5. Part 2 of 2 parts 
Prin'ed in U.S.A. 
ACTIVATION AND CONTROL MECHANISMS OF THE PLASMA 
KININ-FORMING SYSTEM AND ITS RELATIONSHIP TO 
COAGULATION AND FIBRINOLYSIS 
ALLEN P. KAPLAN , M.D. 
Laboratory of Clinical Investigation, National InMitute of Allergy and Infectious Diseases, National Institutes of 
Health, Bethesda, Maryland. U. S. A. 
Hageman factor (Factor XIl) was initially iden-
tified as the surface-activated plasma protein 
which initiates the intrinsic coagulation pathway 
[II. Th is same protein was later shown to be 
required for the initiation of surface-activated 
kinin generation \2 J and fibrin olysis [3, 41 since 
Hageman factor-deficient plasma did not support 
these funct ions. The Hageman facto r substra te 
which acts in the coagulation pathway was desig-
nated plasma th romboplastin ant.ecedent (PTA) 
or Factor XI 15 ]. However. PTA-deficient plasma 
possessed normal Hageman factor-dependent 
fibrinolysis and kinin generation, . uggesting that 
Hageman factor may have other plasma sub-
strates. 
When activated Hageman facto r was isolated 
from human serum, a prealbumin fragment. de-
rived from Hageman factor was discovered [6) 
which was shown to convert prekallikrein to kalli-
krein, the enzyme that digests kininogen to yield 
bradykinin. Thus. prekallikrein was shown to be a 
second Hageman factor su bstrate which is distinct 
from PTA and mediates Hageman factor-depend-
ent kinin fo rm ation. Recently, monospecific anti-
body has been prepared to PTA and prekallikrein . 
and Ouchterlony analysis indicated that they do 
not share antigenic determinants 17). Fragmenta-
tion of H ageman fact.or to yie ld these prealbumin 
fragments was shown to be mediat.ed by enzymatic 
feedback by plasmin [8J and kallikrein [9J. The 
resulting fragment was fully active in kinin forma-
tion and fibrin olysis but was only 2 to 5% as active 
in coagula t ion as the parent molecule. When the 
Hageman facto r-substrat.e mediating fibrinolysis 
was sought.. a plasminogen proactivator [10 J was 
desc ribed which upon activation by Hageman fac-
tor was converted to an active enzyme (plasmino-
gen activator) that directly converts plasminogen 
to plasmin. 
A plasma deficient in prekallikrein was de-
scribed in 1972 [11] and was identified as the 
abnormality p resent in an unusual coagulation 
defect called Fletcher factor deficiency [12.13). 
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Abbreviation: 
PTA: plasma thromboplastin antecedent 
Surface activation of this plasma yields no brady-
kinin , and it also has a diminished rate of Hageman 
factor-dependent coagulation and fibrinolysis [14]. 
Each abnormality was corrected by reconstitution 
with purified prekallikrein. The mechanism of the 
correction of coagulation and fibrinolysis was 
thought to be dependent upon the rate of Hageman 
factor act ivation since this was the only factor com-
mon to each pathway. Furthermore. kallikrein 
could not activate PTA or plasminogen proactiva-
tor. Direct activat ion of Hageman factor by kalli-
krein was then demonstrated [9], and the ability of 
an unfragmented preparat ion of activated Hage-
man factor to correct the coagulation and fib rinoly-
tic abnormalities of prekallikrein deficiency in the 
absence of a surface demonst rated that the abnor-
mality is in the conversion of unactivated to 
activated Hageman factor [14]. Since active kalli -
krein will not correct this deficiency in the absence 
of a surface, t his feedback funct ion of kallikre in is 
upon Hageman factor bound to the surface [7]. 
Recently. plasmas have been described with 
unique abnormalities of Hageman factor-depend-
ent coagulation. fibr inolysis. and kinin generation, 
termed Williams trait [15]. Fitzgerald trait (16 ). 
and Flaujeac trait [111. The corrective factor has 
been independently identified as a high-molecular· 
weight form of kininogen [11.18 J which accounts for 
about 150/.: of the total plasma kininogen. Thi role 
for high-molecular-weight kininogen appears r.o 
precede that of the kallikrein feedback since this 
plasma does not activate its prekallikrein when in-
cubated with kaolin even though its Hageman fac-
tor is normal. Thus. high-molecular-weight kinino-
gen a ppears to be a plasma cofactor needed for 
optimal activation and function of Hageman facto r 
(Fig.). In its absence. insufficient Hageman 
factor is activated to recruit the enzyme feedbacks 
which accelerate each pathway. Si~ilaT functional 
abnormalities have been described in Fit.zgerald 
trait and it has also been shown to be secondary 
to a deficiency of high-molecular-weight kininoge~ 
[19 ]. 
Biologic materials that can activate Hageman 
factor include endotoxin [20 ). uric acid and pyro-
phosphate crystals [21]. and homocysteine crystals 
[22]. Purified soluble collagen does not appear to 
activate Hageman factor [23) while crude collagen 
preparations are active [241, suggesting that insol-
uble collagen or collagen-mucopolysaccharide 
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FIG. Requirements for t.he activation of Hageman factor . 
complexes are required. This may account for the 
activation observed upon incubation "'ith t issues 
such as articular cartilage [25]. Upon activation by 
the surface and high-molecular-weight kininogen, 
activated Hageman factor acts upon each of its 
substrates and both kallikrein and plasmin then 
digest Hageman factor into three fragments. one of 
which corresponds to the prealbum in fragment 
which contains the active site of Hageman factor 
[26]. Plasmin digestion may also yield a larger 
fragment which resists furthe r digestion by plas-
min Or kallikrein but possesses little functional 
difference from the smaller fragment [27]. 
Control of the Hageman factor pathways ma~' be 
modulated by enzymatic digestion of Hageman 
factor since the product retains full activity in 
fibrinolysis and kinin generation but not coagula-
tion . Extrinsic controls are also present which 
depend upon inactivation of each active enzyme by 
one or more plasma enzyme inhibitors. Thus. the 
inhibitor of the first component of complement (CI 
INH) inhibits activated Hageman factor [28-30], 
activated PTA 128]. kallikrein 131]. and plasmin; 
a, macroglobulin inhibits kallikrein [32] and plas-
minogen activator 133]: and a I antitrypsin inhibits 
activated PTA 134] and plasmin. Antithrombin III 
in the presence of heparin rapidly inactivates acti-
vated Hageman factor [35 J. activated PTA [36 J. 
and plasmin 1371 and slowly inactivates kalli-
krein [38]. 
Other functions identified with this proteolytic 
enzyme system include the chemotactic activity of 
kallikrein and plasminogen activator for neutro-
phils [39.40] and mononuclear cells 141], the 
ability of plasmin to activate the CIS subunit of 
the first component of complement 142], and a role 
for Hageman factor in the alternate complement 
pathway 143]. However. there is no evidence that 
activation of Hageman factor, as described above, 
can initiate activation of either complement path-
way in normal plasma. 
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Addendum 
High-molecular-weight kininogen has been shown to 
augment the function of activated Hageman factor upon 
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each of its substrates when it is bound to surfaces [1 -,1 ] or 
is in the t1uid phase as Hagman factor fragments 14]. 
Prekallikrein circulates bound to high-molecular-weight 
kininogen [3_6_7]_ Thus_ high-molecular-weight kinino-
gen is a cofactor in both tbe activation and func-
tion of Hageman fa("tor. 
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